Atorvastatin
Treatment for Metabolic Syndrome
Typical Dosage: 10-80mg daily
Effectiveness
80%
Safety Score
65%
Clinical Trials
37
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10-80mg daily
Time to Effect
2-4 weeks for lipid lowering
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
35(Treat 35 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$200
Side Effect Mgmt:$75
Total Annual:$325
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$382
Atorvastatin Outcomes
for Metabolic Syndrome
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+85%
Common Side Effects
Muscle pain (myalgia)
+7%
Liver enzyme elevation
+2%
New-onset diabetes
+0.5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Atorvastatin in Metabolic Syndrome
Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
NCT01785615COMPLETEDPHASE1, PHASE2
116 participants
INTERVENTIONAL
Rochester, United States
Started: Nov 1, 2004
ROMEO (Rosuvastatin in Metabolic syndrOme)
NCT00395486COMPLETEDPHASE4
258 participants
INTERVENTIONAL
Pusan, South Korea +2 more
Started: Sep 1, 2006
Implications for Treatment of the Metabolic Syndrome
NCT00666029COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Started: Feb 1, 2006
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
NCT00654485COMPLETEDPHASE3
940 participants
INTERVENTIONAL
Started: May 1, 2002
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
NCT00166036COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Atlanta, United States
Started: Sep 1, 2004
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
NCT02503865COMPLETEDPHASE1, PHASE2
351 participants
INTERVENTIONAL
Astana, Kazakhstan
Started: Jan 1, 2003
Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
NCT00409773COMPLETEDPHASE3
1.14K participants
INTERVENTIONAL
Started: Jan 1, 2007
The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women
NCT01072097COMPLETEDNA
30 participants
INTERVENTIONAL
Oulu, Finland
Started: Sep 1, 2006
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
NCT05488067COMPLETEDPHASE4
15 participants
INTERVENTIONAL
Shanghai, China
Started: Mar 22, 2022
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00632840COMPLETEDPHASE4
11 participants
INTERVENTIONAL
Started: Jun 1, 2001
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
NCT01448174COMPLETEDPHASE4
310 participants
INTERVENTIONAL
Nowy Tomyśl, Poland
Started: Oct 1, 2011
Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome
NCT07497776COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Jan 27, 2024
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
NCT04379999COMPLETEDEARLY_PHASE1
43 participants
INTERVENTIONAL
Philadelphia, United States
Started: Sep 10, 2018
Modified Huanglian Wendan Decoction for Metabolic Syndrome
NCT07702669COMPLETEDNA
180 participants
INTERVENTIONAL
Harbin, China
Started: Oct 1, 2023
Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
NCT00157924COMPLETEDPHASE4
190 participants
INTERVENTIONAL
Started: Nov 1, 2005
Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
NCT00665834COMPLETEDPHASE4
18 participants
INTERVENTIONAL
Kingston, Canada +1 more
Started: Apr 1, 2006
Caduet and TLC Intervention in Metabolic Syndrome
NCT03504735COMPLETEDPHASE4
53 participants
INTERVENTIONAL
Started: May 1, 2005
Showing 20 of 41 total trials